Concepedia

Author

Dana Gaffney

Janssen (Belgium)

Also Known As

D Gaffney, D. Gaffney, Dana Gaffney, Dana S. Gaffney

51

Publications

443

Citations

6

H-Index

24

Concepts

All Affiliations

Janssen (Belgium)SpringhouseJanssen (United States)
DG

About

Dana Gaffney is an author at Janssen (Belgium) specializing in radiation oncology, medicine, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

341

2

Cell Biology

3

3

56

3

Pharmacology

3

3

56

4

Cancer Cell Biology

2

2

36

5

Obstetrics

1

1

285

Dana Gaffney

×

6

Publications

421

Citations

6

H-Index

YearCitations

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

Michelle Wilson, Éric Pujade-Lauraine, Daisuke Aoki,

Annals of Oncology

2016

285

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Jayaprakash D. Karkera, Gabriela Martinez Cardona, Katherine Bell,

Molecular Cancer Therapeutics

2017

62

Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent <i>in vitro</i> and <i>in vivo</i> activity, demonstrated in several lung cancer models

Tongfei Wu, Hillary J. Millar, Dana Gaffney,

Cancer Research

2018

25

Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models

Dirk Brehmer, Tongfei Wu, Geert Mannens,

Cancer Research

2017

20

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Bertrand Coiffier, Weimin Li, Erin D. Henitz,

Clinical Cancer Research

2013

18

Abstract 950: In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models

Hillary J. Millar, Dirk Brehmer, Tinne Verhulst,

Cancer Research

2019

11

Page 1